Peer review articles planned or manuscripts submitted for peer review approval and publication in the forthcoming issues.
Online First articles have been peer reviewed, accepted for publication and published online; they have not yet been assigned to a journal issue. When an article is published in a journal issue with the assigned page number, it will be removed from the ‘Forthcoming Issue’ page.
Online First articles are copyedited by the science editors and the editorial production team; typeset, proofread and approved by the author(s) before publication. We aim to post each article within six weeks of acceptance and within two weeks after final proofreading approval by the author. Online First articles are in searchable full text, with the initial online publication date included in the final print version.
Articles appearing on the ‘Forthcoming Issue’ page are in the order of the Journal Editorial Sections. You may also view the abstract by clicking on the article link.
Subscribe now to the print or PDF copy of GaBI Journal to view full information of the following manuscripts*.
Latest features in GaBI Journal, 2020, Issue 3 / Professor Philip D Walson, MD
Is the local tolerance of injectable biosimilars too underestimated? / Professor Alain Astier, PharmD, PhD
Quality standards for biopharmaceuticals: the importance of good manufacturing practice / Elwyn Griffiths, DSc, PhD
A white paper: US biosimilars market on pace with Europe / Madelaine A Feldman, MD, FACR, Michael S Reilly, Esq
Systematic analysis of injection-site pain and reactions caused by subcutaneous administration of the adalimumab biosimilar FKB327 versus the adalimumab reference product via different delivery methods / Rieke Alten, MD; Herbert Kellner, MD; Malcolm Boyce, MD; Takuma Yonemura, MD; Takahiro Ito; Mark C Genovese, MD
Qualitative survey-based evaluation of operability and convenience for the etanercept biosimilar YLB113 in a unique injection pen in patients with rheumatoid arthritis / Toshihiko Hibino, Tomohiko Yoshida, Akira Sagawa, Ikuko Masuda,Takaaki Fukuda
European prescribers’ attitudes and beliefs on biologicals prescribing and automatic substitution / Madelaine Feldman, MD, FACR; Michael S Reilly, Esq
Physicochemical stability of the bevacizumab biosimilar, ABP 215, after preparation and storage in intravenous bags / Jolita Seckute, PhD, Ingrid Castellanos, PhD, Steven Bane, PhD
Local policies on biosimilars: are they designed to optimize use of freed resources? / Bertolani A, PhD, Jommi C, MS
Pharmaceutical Data Integrity: issues, challenges and proposed solutions for manufacturers and inspectors / Chan Lai Wah, BSc (Pharm) (Hons), PhD; Professor Sia Chong Hock, BPharm, MSc; Vernon Tay, BSc (Pharm) (Hons); Vimal Sachdeva, MSc
Pelmeg®, a biosimilar pegfilgrastim developed in the context of evolving regulatory guidelines / Karsten Roth, Hendrik Wessels, Josef Höfler, Ulrike Scholz, Dirk Lehnick
Regulatory pathway for approval of ‘biosimilars’ in Iran / Jalal Naeli, MD
Local policies on biosimilars – are they designed to optimize use of freed resources; findings and implications? / Brian Godman, BSc, PhD; Eleonora Allocati, BSc, MSc; Evelien Moorkens, BSc, MSc; Hye-Young Kwon, BPharm, MPH, PhD
3rd Colombian educational workshop on regulatory assessment of biosimilars 2019 – Report / Professor John-Joseph Borg, PhD; Yolanda Elias Gramajo, MD; Professor Andrea Laslop, MD; Robin Thorpe, PhD, FRCPath; Jian Wang, MD, PhD
Click here for more details on the educational series.
Contact us for an updated list of editorial topics in forthcoming issues.
*Editorial content may differ from final version of manuscript published in print.